ArticleCurrent ophthalmology reports2017
Update on the Management of High-Risk Penetrating Keratoplasty.
Article in Current ophthalmology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Outcomes of sequential keratoplasty for bilateral gelatinous drop-like corneal dystrophy: A case report.Medicine · 2026Article
- Long-Term Graft Survival Following Penetrating Keratoplasty in Eyes with Preoperative Corneal Neovascularization.Ophthalmology and therapy · 2026Article
- Indications and long-term outcomes of repeat optical penetrating keratoplasty.Indian journal of ophthalmology · 2026Article
- Etiology, surgical management, and outcomes of patients with scleral thinning.The Journal of international medical research · 2026Observational
- Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study.International ophthalmology · 2026Observational
- Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience.Ophthalmology science · 2026Article
- Long-Term Graft Survival and Visual Outcomes in Deep Anterior Lamellar Keratoplasty (DALK): A Narrative Review.Journal of ophthalmology · 2026Review
- Tacrolimus eye drops treatment for recurrent exposure of the Ahmed glaucoma valve tube.European journal of medical research · 2025Article
- Topical Tacrolimus in the Management of High-Risk Keratoplasty: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Influential Factors and Outcome of High-Risk Keratoplasty in a Tertiary Referral Corneal Center: A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Intraoperative Optical Coherence Tomography (OCT)-Guided Femtosecond Laser-Assisted Descemet Membrane Endothelial Keratoplasty (iFAD).Bioengineering (Basel, Switzerland) · 2024Article
- Pseudochamber-Protected Keratoplasty (PPK) with a New Inter-Corneal Surgical Device Implant Technique in High-Risk Cases.Journal of clinical medicine · 2024Article
- Ten-year outcomes of repeat keratoplasty for optical indications.Frontiers in medicine · 2024Article
- Biocompatibility and Transplantation Efficacy of the C-Clear Artificial Cornea in a Rabbit Chemical Burn Model.Bioengineering (Basel, Switzerland) · 2023Article
- Genipin increases extracellular matrix synthesis preventing corneal perforation.The ocular surface · 2023Article
- Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study.BMC ophthalmology · 2022Article
- Effects of femtosecond laser-assisted trephination on donor tissue in liquid interface as compared to applanated interface.Acta ophthalmologica · 2022Article
- Mesenchymal stromal cells for corneal transplantation: Literature review and suggestions for successful clinical trials.The ocular surface · 2021Review
- Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.American journal of ophthalmology · 2020Article
- Predictive biomarkers for graft rejection in pig-to-non-human primate corneal xenotransplantation.Xenotransplantation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
purpose of reviewIn this article, we review the indications and latest management of high-risk penetrating keratoplasty. RECENT
findingsDespite the immune-privilege status of the cornea, immune-mediated graft rejection still remains the leading cause of corneal graft failure. This is particularly a problem in the high-risk graft recipients, namely patients with previous graft failure due to rejection and those with inflamed and vascularized corneal beds. A number of strategies including both local and systemic immunosuppression are currently used to increase the success rate of high-risk corneal grafts. Moreover, in cases of limbal stem cell deficiency, limbal stem cells transplantation is employed. SUMMARY: Corticosteroids are still the top medication for prevention and treatment in cases of corneal graft rejection. Single and combined administration of immunosuppressive agents e.g. tacrolimus, cyclosporine and mycophenolate are promising adjunctive therapies for prolonging graft survival. In the future, cellular and molecular therapies should allow us to achieve immunologic tolerance even in high-risk grafts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.